NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry
Molecules · 08.05.2025 · 30 (10) · 2095
DOI: 10.3390/molecules30102095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 08.05.2025. Verfasst von Claudia G Chambers und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Missouri, Columbia, MO 65201, USA. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Heterocyclic Compounds, Acetates, Coordination Complexes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, VA Research Career Scientist Award, VA Merit Award.
Abstract (Originalsprache)
Effective molecular imaging and targeted cancer therapy rely on receptor-specific targeted delivery systems that are both metabolically stable and kinetically inert for optimal in vivo performance. Until now, no single metal complexing agent has demonstrated the versatility to coordinate metals across the periodic table while maintaining the kinetic inertness required for clinical theranostic applications. Therefore, enhancing the in vivo kinetic stability of radiolabeled, cell-targeting, biologically active compounds remains a critical goal to minimize unintended accumulation of radioactivity in collateral tissues. This review describes the usage of NOTA [NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid] and derivatives of NOTA, a metal complexing agent that has been found to have the ability to effectively coordinate with a wide range of radiometals, including metal-radiohalogens, to form stable complexes. This enables the development of new cell-targeting small molecule and peptide conjugates with the potential to resist demetallation in vivo, thereby reducing radionuclide uptake in non-target tissues. Herein, we discuss the design and development of NOTA-based, cell-targeting, small molecules having very high affinity and selectivity for the GRPR (Gastrin-Releasing Peptide Receptor), the SSTR2 (Somatostatin Receptor Subtype 2), and the MC1R (Melanocortin-1) receptors that are present on the surfaces of numerous solid primary human tumors and their metastatic counterparts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Missouri, Columbia, MO 65201, USA.
- Molecular Imaging and Theranostics Center, University of Missouri, Columbia, MO 65201, USA.
- Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
- Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA.
- Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo 13759, Egypt.
- Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65201, USA.
ORCID-Profile: Claudia G Chambers, Tamer M Sakr
Förderung
- BLRD VA
- VA Research Career Scientist Award
- VA Merit Award
- NCI NIH HHS
- NIH HHS
- NIH Grants
- Fulbright Foundation/Fellowship
Zitieren
APA
Chambers, C. G., Wang, J., Sakr, T. M., Miao, Y., & Smith, C. J. (2025). NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry. Molecules, 30(10), 2095. https://doi.org/10.3390/molecules30102095
Vancouver
Chambers CG, Wang J, Sakr TM, Miao Y, Smith CJ. NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry. Molecules. 2025;30(10):2095. doi:10.3390/molecules30102095
BibTeX
@article{Chambers2025,
author = {Chambers, Claudia G and Wang, Jing and Sakr, Tamer M and Miao, Yubin and Smith, Charles J},
title = {NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry},
journal = {Molecules},
year = {2025},
volume = {30},
number = {10},
pages = {2095},
doi = {10.3390/molecules30102095}
}
EUVIMED